Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Double-blind Trial of Platinum Doublet Chemotherapy With or Without Pembrolizumab in Resectable Stage II–IIIB (N2) NSCLC
2017-001832-21Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Nov 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Pembrolizumab + platinum doublet with Placebo + platinum doublet (2 arms). Primary endpoint: Event-free survival (EFS). Started Nov 2017; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-001832-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001832-21.